vs
Pure Storage, Inc.（PSTG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Pure Storage, Inc.的季度营收约是Revvity的1.2倍（$964.5M vs $772.1M），Revvity净利率更高（12.7% vs 5.7%，领先7.1%），Pure Storage, Inc.同比增速更快（16.0% vs 5.9%），Revvity自由现金流更多（$161.8M vs $52.6M），过去两年Pure Storage, Inc.的营收复合增速更高（10.5% vs 9.0%）
Pure Storage是美国上市科技企业，总部位于加利福尼亚州圣克拉拉，成立于2009年，2011年正式推出自研全闪存数据存储软硬件产品，2015年上市前累计获得超4.7亿美元风险投资，营收长期保持高速增长态势。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PSTG vs RVTY — 直观对比
营收规模更大
PSTG
是对方的1.2倍
$772.1M
营收增速更快
PSTG
高出10.2%
5.9%
净利率更高
RVTY
高出7.1%
5.7%
自由现金流更多
RVTY
多$109.2M
$52.6M
两年增速更快
PSTG
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $964.5M | $772.1M |
| 净利润 | $54.8M | $98.4M |
| 毛利率 | 72.3% | — |
| 营业利润率 | 5.6% | 14.5% |
| 净利率 | 5.7% | 12.7% |
| 营收同比 | 16.0% | 5.9% |
| 净利润同比 | -13.9% | 3.9% |
| 每股收益（稀释后） | $0.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PSTGRVTY
| Q4 25 | $964.5M | $772.1M | ||
| Q3 25 | $861.0M | $698.9M | ||
| Q2 25 | $778.5M | $720.3M | ||
| Q1 25 | $879.8M | $664.8M | ||
| Q4 24 | $831.1M | $729.4M | ||
| Q3 24 | $763.8M | $684.0M | ||
| Q2 24 | $693.5M | $691.7M | ||
| Q1 24 | $789.8M | $649.9M |
净利润PSTGRVTY
| Q4 25 | $54.8M | $98.4M | ||
| Q3 25 | $47.1M | $46.7M | ||
| Q2 25 | $-14.0M | $53.9M | ||
| Q1 25 | $42.4M | $42.2M | ||
| Q4 24 | $63.6M | $94.6M | ||
| Q3 24 | $35.7M | $94.4M | ||
| Q2 24 | $-35.0M | $55.4M | ||
| Q1 24 | $65.4M | $26.0M |
毛利率PSTGRVTY
| Q4 25 | 72.3% | — | ||
| Q3 25 | 70.2% | 53.6% | ||
| Q2 25 | 68.9% | 54.5% | ||
| Q1 25 | 67.5% | 56.5% | ||
| Q4 24 | 70.1% | — | ||
| Q3 24 | 70.7% | 56.3% | ||
| Q2 24 | 71.5% | 55.7% | ||
| Q1 24 | 72.0% | 54.6% |
营业利润率PSTGRVTY
| Q4 25 | 5.6% | 14.5% | ||
| Q3 25 | 0.6% | 11.7% | ||
| Q2 25 | -4.0% | 12.6% | ||
| Q1 25 | 4.8% | 10.9% | ||
| Q4 24 | 7.2% | 16.3% | ||
| Q3 24 | 3.3% | 14.3% | ||
| Q2 24 | -6.0% | 12.4% | ||
| Q1 24 | 7.3% | 6.8% |
净利率PSTGRVTY
| Q4 25 | 5.7% | 12.7% | ||
| Q3 25 | 5.5% | 6.7% | ||
| Q2 25 | -1.8% | 7.5% | ||
| Q1 25 | 4.8% | 6.4% | ||
| Q4 24 | 7.7% | 13.0% | ||
| Q3 24 | 4.7% | 13.8% | ||
| Q2 24 | -5.0% | 8.0% | ||
| Q1 24 | 8.3% | 4.0% |
每股收益（稀释后）PSTGRVTY
| Q4 25 | $0.16 | $0.86 | ||
| Q3 25 | $0.14 | $0.40 | ||
| Q2 25 | $-0.04 | $0.46 | ||
| Q1 25 | $0.13 | $0.35 | ||
| Q4 24 | $0.19 | $0.77 | ||
| Q3 24 | $0.10 | $0.77 | ||
| Q2 24 | $-0.11 | $0.45 | ||
| Q1 24 | $0.22 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $852.8M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $4.2B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PSTGRVTY
| Q4 25 | $852.8M | $919.9M | ||
| Q3 25 | $887.8M | $931.4M | ||
| Q2 25 | $739.3M | $991.8M | ||
| Q1 25 | $723.6M | $1.1B | ||
| Q4 24 | $894.6M | $1.2B | ||
| Q3 24 | $965.0M | $1.2B | ||
| Q2 24 | $900.6M | $2.0B | ||
| Q1 24 | $702.5M | $1.7B |
股东权益PSTGRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.3B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.3B | $7.8B |
总资产PSTGRVTY
| Q4 25 | $4.2B | $12.2B | ||
| Q3 25 | $4.0B | $12.1B | ||
| Q2 25 | $3.8B | $12.4B | ||
| Q1 25 | $4.0B | $12.4B | ||
| Q4 24 | $3.9B | $12.4B | ||
| Q3 24 | $3.8B | $12.8B | ||
| Q2 24 | $3.6B | $13.4B | ||
| Q1 24 | $3.7B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $116.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $52.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 5.5% | 21.0% |
| 资本支出强度资本支出/营收 | 6.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.12× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $566.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PSTGRVTY
| Q4 25 | $116.0M | $182.0M | ||
| Q3 25 | $212.2M | $138.5M | ||
| Q2 25 | $283.9M | $134.3M | ||
| Q1 25 | $208.5M | $128.2M | ||
| Q4 24 | $97.0M | $174.2M | ||
| Q3 24 | $226.6M | $147.9M | ||
| Q2 24 | $221.5M | $158.6M | ||
| Q1 24 | $244.4M | $147.6M |
自由现金流PSTGRVTY
| Q4 25 | $52.6M | $161.8M | ||
| Q3 25 | $150.1M | $120.0M | ||
| Q2 25 | $211.6M | $115.5M | ||
| Q1 25 | $152.4M | $112.2M | ||
| Q4 24 | $35.2M | $149.8M | ||
| Q3 24 | $166.6M | $125.6M | ||
| Q2 24 | $172.7M | $136.6M | ||
| Q1 24 | $200.9M | $129.7M |
自由现金流率PSTGRVTY
| Q4 25 | 5.5% | 21.0% | ||
| Q3 25 | 17.4% | 17.2% | ||
| Q2 25 | 27.2% | 16.0% | ||
| Q1 25 | 17.3% | 16.9% | ||
| Q4 24 | 4.2% | 20.5% | ||
| Q3 24 | 21.8% | 18.4% | ||
| Q2 24 | 24.9% | 19.7% | ||
| Q1 24 | 25.4% | 20.0% |
资本支出强度PSTGRVTY
| Q4 25 | 6.6% | 2.6% | ||
| Q3 25 | 7.2% | 2.6% | ||
| Q2 25 | 9.3% | 2.6% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 7.4% | 3.4% | ||
| Q3 24 | 7.9% | 3.3% | ||
| Q2 24 | 7.0% | 3.2% | ||
| Q1 24 | 5.5% | 2.7% |
现金转化率PSTGRVTY
| Q4 25 | 2.12× | 1.85× | ||
| Q3 25 | 4.50× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 4.91× | 3.03× | ||
| Q4 24 | 1.52× | 1.84× | ||
| Q3 24 | 6.35× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 3.74× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PSTG
| US | $683.2M | 71% |
| Non Us | $281.3M | 29% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
